300
Participants
Start Date
October 30, 2021
Primary Completion Date
June 30, 2023
Study Completion Date
October 30, 2023
Dulaglutide Injection
Dulaglutide injection was injected subcutaneously at standard dose and frequency for consecutive 12 months in patients with type 2 diabetes and diabetic kidney disease. Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.
Department of Endocrinology, Xuzhou
The Affiliated Hospital of Xuzhou Medical University
OTHER